AEON Biopharma Inc. Class A Common Stock (AEON)
Stock · AMEX · Health Care
$0.2394as of 10/16/2026
Price chart
Active signals
AEON Signal Track Record
How signals performed across all stocks →What AEON's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 20 | -8.4% | 40% | September 30, 2026 |
| Bollinger Band Breakdown | 16 | +7.0% | 63% | August 19, 2026 |
| Bollinger Band Breakout | 14 | +10.8% | 64% | January 21, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -2.2% | 25% | April 29, 2026 |
| Any 20-session window (baseline) | -6.0% | 43% |
Computed by MarketWall from daily closing prices since October 18, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AEON
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-tra…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- www.aeonbiopharma.com/
Fundamentals
- 1-day range
- $0.236$0.2476
- Market cap
- $13.80M
- P/E (trailing)
- —
- P/E (forward)
- -0.94
- EPS (trailing)
- $-3.58
- Dividend yield
- —
- Beta
- 0.65
- Avg. volume
- 7.65M
Forecasts
5 analyst ratings
AEON Biopharma Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- AEONAEON Biopharma Inc. Class A Common Stock$0.232▼ 4.53%Market cap $13.80MP/E —$0.1772$1.45
- PTNPalatin Technologies Inc. Common Stock$6.02▼ 7.24%Market cap $14.00MP/E 92.55$5.61$31
- AKTXAkari Therapeutics plc ADS$8.18▼ 7.47%Market cap $14.14MP/E Infinity$3.02$39.64
- COCPCocrystal Pharma Inc. Common Stock$1.02▼ 0.97%Market cap $14.20MP/E —$0.76$2.03
- KALAKALA BIO Inc. Common Stock$0.19▼ 1.04%Market cap $14.25MP/E —$0.2593$95.5
- GTBPGT Biopharma Inc. Common Stock$7.03▼ 4.48%Market cap $13.35MP/E —$4.91$34.25
- PBMPsyence Biomedical Ltd. Common Shares$4.22▼ 2.31%Market cap $13.31MP/E —$1.92$143.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AEON AEON Biopharma Inc. Class A Common Stock | $13.80M | — | $0.232 | ▼ 4.53% | $0.1772$1.45 |
| PTN Palatin Technologies Inc. Common Stock | $14.00M | 92.55 | $6.02 | ▼ 7.24% | $5.61$31 |
| AKTX Akari Therapeutics plc ADS | $14.14M | Infinity | $8.18 | ▼ 7.47% | $3.02$39.64 |
| COCP Cocrystal Pharma Inc. Common Stock | $14.20M | — | $1.02 | ▼ 0.97% | $0.76$2.03 |
| KALA KALA BIO Inc. Common Stock | $14.25M | — | $0.19 | ▼ 1.04% | $0.2593$95.5 |
| GTBP GT Biopharma Inc. Common Stock | $13.35M | — | $7.03 | ▼ 4.48% | $4.91$34.25 |
| PBM Psyence Biomedical Ltd. Common Shares | $13.31M | — | $4.22 | ▼ 2.31% | $1.92$143.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 10/2/2026
- Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2benzinga · 10/1/2026
- Apple To $355? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · 10/1/2026
- Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2Benzinga · 10/1/2026
- Discover the most active stocks in Wednesday's session.ChartMill · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 9/30/2026
- AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450Yahoo · 9/30/2026
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga · 9/14/2026
- On Friday, there are stocks with unusual volume. Let's take a look.ChartMill · 9/11/2026
Insider Activity
Insider Actions →- LYNCH TIMOTHY P · August 19, 2026 · Buy1.15M @ $0.2117
- Forth Marc · June 17, 2026 · Grant222.7K
- Carter Eric G · June 17, 2026 · Grant222.7K
- FISCHER JOST · June 17, 2026 · Grant222.7K
- Shelley B. Thunen · June 17, 2026 · Grant222.7K
- Robert J. Palmisano · June 17, 2026 · Grant222.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.83M
- Total value held
- $2.79M
- Institutional holders
- 22
- Unknown2.53M
- Unknown90.5K
- Unknown87.1K
- Unknown42.4K
- Unknown20.4K
- Unknown20.0K
- Unknown16.4K
- Unknown11.5K
- Unknown4.2K
- Unknown2.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan
AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan. AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.